. 2021 Dec 18;107(5):1461–1469. doi: 10.1210/clinem/dgab905
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Figure 1.
Network of evidence for semaglutide vs high-dose dulaglutide. Abbreviations: QW, once weekly.